What is the extent of disparities in cancer clinical trials among low- and middle-income countries?

Study uncovers unequal development over 20 years, with economic growth playing a role

2025-10-20

(Press-News.org) New research reveals that the number and complexity of cancer clinical trials since 2001 have varied across low- and middle-income countries (LMICs), with economic growth contributing to disparities, but only to a certain extent. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Although LMICs are expected to experience the greatest global burden of cancer in the coming years, cancer clinical trials are disproportionally concentrated in high-income countries. Because evidence suggests that LMICs have increased the number of cancer clinical trials over the last few decades, researchers investigated disparities in the number and complexity of such trials among LMICs over time and according to economic changes.

Between 2001 and 2020, a total of 16,977 cancer clinical trials in LMICs were registered. The Asian countries of China and South Korea experienced strong economic growth and increases in clinical trials. Similar trends, though less impressive, were observed in East European countries and the West Asian/Southern European country of Turkey. Conversely, South and Southeast Asian countries like India, Thailand, and Vietnam—which also experienced strong economic growth—had mainly inconsistent growth in clinical trials. The North and South American countries of Argentina, Brazil, and Mexico were able to increase their number of clinical trials despite relative economic stagnation. Among African countries, Egypt showed strong economic growth with a corresponding increase in clinical trials, but no such correlation was seen in South Africa.

Taken together, the findings suggest that economic growth is a contributor but not the single determinant of cancer clinical trial growth among LMICs.

“We believe these data offer valuable insights for LMICs aiming to enhance clinical research,” said senior author Max S. Mano, MD, PhD, of the Latin American Cooperative Oncology Group and Einstein Hospital Israelita, in Brazil.

Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com

Full Citation:
“Disparities in Cancer Clinical Trials Among Low- and Middle-income Countries: a 20-year Analysis.” Fanny G.A. Cascelli, Milene C. Mitsuyuki, Gustavo Werutsky, Carlos H.E. Barrios, Malu V.R. Barbosa, Michelle S. Almeida, and Max S. Mano. CANCER; Published Online: October 20, 2025 (DOI: 10.1002/cncr.70067).
URL Upon Publication: http://doi.wiley.com/10.1002/cncr.70067

Author Contact: Cauana Tavares, of the Latin American Cooperative Oncology Group, at cauana.tavares@lacog.group.

About the Journal
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on X @JournalCancer and Instagram @ACSJournalCancer, and stay up to date with the American Cancer Society Journals on LinkedIn.

About Wiley     
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.

END

ELSE PRESS RELEASES FROM THIS DATE:

Invisible poison: Airborne mercury from gold mining is contaminating African food crops, new study warns

2025-10-20

In a recent study published today in the European Geosciences Union (EGU) journal Biogeosciences, scientists have confirmed that mercury pollution from artisanal and small-scale gold mining (ASGM) is contaminating food crops not through the soil, as previously believed, but directly from the air. Driven by the surging price of gold, which has increased by more than tenfold since 2000, the rapid expansion of unregulated mining in these regions raises urgent questions about food security, human health, and environmental justice The study, conducted by an international team of scientists led by Excellent ...

Nearly half of Finns with chronic conditions find medication therapy a burden

2025-10-20

According to a recent study, 44% of people with chronic conditions who responded to a population-based survey experienced medication-related burden (MRB). The burden was most common among people with diabetes, heart disease, rheumatic disease or some other musculoskeletal disorder. The greatest burden was caused by factors associated with health care, such as fragmented care and the cost of medicines, as well as adverse drug reactions or concerns about them. “Other factors linked with MRB were poor health status, limits on functional capacity and low income,” says Pharmacist and Doctoral Researcher Heidi Mikkola from the School of Pharmacy at the University of ...

Do animals fall for optical illusions? What fish and birds can teach us about perception

2025-10-20

Have you ever looked at two circles of exactly the same size and sworn one was larger? If so, your eyes have been tricked by the Ebbinghaus illusion, a classic example of how context can shape what we see. Place a circle among other smaller circles, and it seems bigger; place it among larger ones, and it shrinks before our eyes. This illusion fascinates psychologists because it reveals that perception is not a mirror of the outside world but a clever construction of the brain. But here is the question that inspired our study: do other animals fall for the same tricks? If a tiny fish or a bird perceives ...

New guideline emphasizes conversations about mood, mental health between patients and clinicians

2025-10-20

Depression is a mental illness, and support for depression can improve emotions, thoughts, and well-being. A new guideline from the Canadian Task Force on Preventive Health Care recommends that patients aged 18 and older talk to their health care providers about depression rather than undergo routine screening with standard tools, like questionnaires. The guideline is published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250237. In Canada, depression is common, with about 1 in 10 people (without bipolar disorder) experiencing depression in their lifetimes. It negatively affects how a person ...

Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure

2025-10-20

Philadelphia, October 20, 2025 – Peanuts represent one of the most common causes of immunoglobulin E (IgE)-mediated, or anaphylactic, food allergies in children, yet a landmark study found that early introduction of peanut to infants may lower their risk of developing this allergy. Now, a new study from researchers from Children’s Hospital of Philadelphia (CHOP) has shown that the rates of diagnosis of peanut and other IgE-mediated food allergies have declined since the adoption of guidelines encouraging early introduction practices. The findings, published today ...

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

2025-10-19

VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma In this trial, VT3989 demonstrated notable antitumor activity, with a disease control rate of 86% at the clinically optimized dosing levels These data provide the first clinical proof-of-concept for effectively drugging the Hippo-YAP-TEAD pathway VT3989 was awarded Orphan Drug Designation and Fast Track Designation for the treatment of mesothelioma by the FDA BERLIN, OCTOBER 19, 2025 ― The first-in-class YAP-TEAD inhibitor ...

Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer

2025-10-19

Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found. The observation by researchers at the University of Florida and the University of Texas MD Anderson Cancer Center is a defining moment in a decade-plus of research testing mRNA-based therapeutics designed to “wake up” the immune system against cancer. Building on a previous UF study, the observation also marks a significant step toward a long-awaited universal cancer vaccine to ...

ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy

2025-10-19

Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after treatment as those who never received a vaccine These findings have prompted a randomized Phase III trial to determine if mRNA COVID vaccines should be part of the standard of care for this type of therapy If validated, findings could significantly increase the number of patients who benefit from immunotherapy BERLIN, OCTOBER 19, 2025 ― Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning ...

Drug combo cuts risk of death in advanced prostate cancer by 40%

2025-10-19

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination therapy, which adds a drug called enzalutamide to commonly prescribed hormone therapy, reduced deaths in patients with recurrent prostate cancer after surgery or radiation for whom other treatments are no longer an option. The trial results were published in The New England Journal of Medicine (NEJM) with simultaneous presentation during the European Society for Medical Oncology Congress (ESMO) Oct. 19 in Berlin. “After ...

ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors

2025-10-19

BERLIN October 19, 2025 – Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy. These findings, which stem from the ASCENT-03 trial in triple-negative breast cancer co-led by investigators at Dana-Farber Cancer Institute, are presented today at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. They are also published simultaneously in the New England Journal ...

What is the extent of disparities in cancer clinical trials among low- and middle-income countries?

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: